Rexulti brexpiprazole regulatory update

FDA approved an NDA from Otsuka for Rexulti brexpiprazole to treat schizophrenia and as an adjunct treatment for major depressive disorder (MDD). Otsuka and H. Lundbeck plan to launch Rexulti in early August. Lundbeck declined to disclose the wholesale acquisition cost (WAC) for the product, which is a partial agonist of the dopamine D2 receptor with affinity for multiple serotonin receptors. ...